3-N-吡啶基丁酰胺酸 | 25604-13-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 3-N-吡啶基丁酰胺酸
• 中文别名: N-(3-吡啶基)丁酰胺酸；4-氧代-4-(3-吡啶氨基)丁酸；4-氧代-4-(3-吡啶基氨基)丁酸；N-吡啶-3-基-丁酰胺酸
• 英文名称: succinic acid 3-pyridylmonoamide
• 英文别名: succinic acid N-(3-pyridyl)amide；N-pyridin-3-yl-succinamic acid；N-Pyridin-3-yl-succinamic acid；N-(3-Pyridyl)-succinamic acid；4-oxo-4-(pyridin-3-ylamino)butanoic acid
• CAS: 25604-13-1
• 化学式: C₉H₁₀N₂O₃
• mdl: MFCD00124271
• 分子量: 194.19
• InChiKey: CRCDHMGBWOILNF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  79.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-N-吡啶基丁酰胺酸 在 ammonium peroxydisulfate 、 silver nitrate 、 三氟乙酸 作用下， 以 水 为溶剂， 反应 6.0h， 以60%的产率得到3-氨基吡啶
  参考文献：
  名称：

  Minisci反应用于合成氮杂杂环的范围和局限性

  摘要：

  描述了通过应用Minisci自由基环化反应来制备几类氮杂杂环的尝试。竞争性的β断裂，水解裂解和内酯化反应是采用这种策略合成此类靶标的主要障碍。

  DOI：

  10.1016/j.tetlet.2009.09.112
• 作为产物：
  描述：

  N-Pyridin-3-yl-succinamic acid benzyl ester 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以66%的产率得到3-N-吡啶基丁酰胺酸
  参考文献：
  名称：

  Novel malonamide derivatives as potent κ opioid receptor agonists

  摘要：

  A novel series of malonamide derivatives was synthesized. These amides were shown to be potent and selective kappa opioid receptor agonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.053

文献信息

• Substituted amides and hydrazides of 1,4-dicarboxylic acids. part 8. Synthesis and hypoglycemic activity of substituted succinic acid amides and hydrazides
  作者：N. V. Kolotova、A. V. Dolzhenko、V. O. Koz’minykh、V. P. Kotegov、A. T. Godina

  DOI：10.1007/bf02974937

  日期：1999.12

  hydrazides of 1,4-dicarboxylic acids contain compounds possessing hypoglycemic properties [2 7], this activity being most pronounced in substituted hydrazides of succinic acid with beterylamide terminal fragments [6, 8]. In continuation of the search for new hypoglycemic agents, we have synthesized a series of hetery]amides (IHI) and acylhydrazides ( IVIX) of succinic acid and studied their properties

  据报道，1,4-二羧酸的酰胺和酰肼含有具有降血糖特性的化合物 [2-7]，这种活性在琥珀酸的取代酰肼中最为显着 [6, 8]。在继续寻找新的降血糖药的过程中，我们合成了一系列琥珀酸杂杂]酰胺（IHI）和酰肼（IVIX）并研究了它们的性质。R. v fO。
• Tetracyclic Anthraquinone Derivatives
  申请人：Tianjin Hemay Bio-Tech Co., Ltd

  公开号：US20150166595A1

  公开（公告）日：2015-06-18

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , W, n are defined as in the present application.

  公开了一种由式（I）表示的化合物及其药用可接受的盐，其中R1、R2、R3、R4、R5、W、n的定义如本申请中所述。
• Amide derivatives and methods of their use
  申请人：Dolle E. Roland

  公开号：US20050107355A1

  公开（公告）日：2005-05-19

  Amide derivatives of the general formulae Ia and Ib: are disclosed. Pharmaceutical compositions containing these compounds, and methods for their use, inter alia, for treating and/or preventing gastrointestinal disorders, pain, and pruritus are also disclosed.

  一般式Ia和Ib的酰胺衍生物已被披露。还披露了含有这些化合物的药物组合物，以及用于治疗和/或预防胃肠道疾病、疼痛和瘙痒等的方法。
• Tetracyclic anthraquinone derivatives
  申请人：TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD.

  公开号：US10294260B2

  公开（公告）日：2019-05-21

  Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application.

  公开了一种由式 (I) 代表的化合物及其药学上可接受的盐、 其中 R1、R2、R3、R4、R5、W、n 的定义与本申请相同。还公开了一种治疗癌症的方法，包括向有需要的受试者施用治疗有效量的式 (I) 所代表的化合物或其药学上可接受的盐。根据本申请的化合物及其盐具有良好的抗癌和/或抗肿瘤活性、良好的水溶性和稳定性，以及在动物体内良好的耐受性。本申请还公开了一种制备式（I）所代表的化合物的工艺。
• TETRACYCLIC ANTHRAQUINONE DERIVATIVES
  申请人：Tianjin Hemay Bio-Tech Co., Ltd.

  公开号：EP2824108B1

  公开（公告）日：2017-04-19